Skip to main content
Fig. 5 | BMC Complementary Medicine and Therapies

Fig. 5

From: Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway

Fig. 5

Effects of FC-treatment on the hepatic lipid metabolism-related genes expressions in HFD-induced obese mice. Hepatic lipid metabolism-related genes expressions, such as DNL A, β-oxidation B, FFA uptake C and VLDL export D were examined. E The level of hepatic FFA was measured. DNL, de novo lipogenesis; FFA, free fatty acid; VLDL, very low density lipoprotein; Srebp-1c, sterol response element binding protein-1c; Ppar, peroxisome proliferator activated receptor; Fas, fatty acid synthase; Acc, Acetyl-CoA; Cpt1, carnitine palmitoyltransferase 1; Mcad, medium chain acyl dehydrogenase; CD36, fatty acid translocase; Fabp1, fatty acid binding protein 1; Fatp1, fatty acid transport protein 1; ApoB, Apo lipoprotein B; ApoE, Apo lipoprotein E; Mttp, microsomal triglyceride transfer protein. Sim (40 mg/kg) acted as the positive control group. Each value represents as means ± S.E.M. of triplicate experiments. # P < 0.01 as compared with the control group. * P < 0.05, ** P < 0.01, and *** P < 0.001 as compared with the HFD-induced group

Back to article page